HROW — HARROW, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1360214 ·
Last close
$29.52
Market Cap
$1.11B
52W High
$54.85
52W Low
$25.76
ADV30
695,123
Next earnings
2026-11-09
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 99,297,000 | 74,903,000 | 11,471,000 | 9,757,000 | 443,021,000 | 75,336,000 | 414,187,000 |
| Jun 2026 | 70,661,000 | 50,363,000 | -11,007,000 | -17,270,000 | 416,816,000 | 83,889,000 | 401,971,000 |
| Mar 2026 | 44,203,000 | 27,045,000 | -22,080,000 | -27,602,000 | 419,543,000 | 94,644,000 | 391,192,000 |
| Dec 2025 | 89,092,000 | 70,624,000 | 15,591,000 | 6,626,000 | 399,482,000 | 72,927,000 | 347,391,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-18,952,000
Investing CF
$-23,873,000
Financing CF
$43,871,000
CapEx
$-19,515,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.78
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-191,639,000
Inventory
$19,220,000
Receivables
$155,308,000
ST Investments
—
EBIT TTM
$-1,033,000
Pretax Income TTM
$-24,187,000
Interest Exp TTM
$23,154,000
Analysts
8
Yahoo Snapshot (yfinance, live)
Total Revenue
$303,252,992
EBITDA
$15,743,000
Free Cash Flow
$-34,198,876
Enterprise Value
$1,354,194,816
Total Cash
$76,805,000
Total Debt
$300,856,000
Shares Out
37,533,160
Trailing EPS
$-0.81
Book Value
$0.78
ROE
-75.5%
ROA
-0.9%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 272,303,000 | 30,515,000 | -5,139,000 | 399,482,000 | 347,391,000 | 52,446,000 | 43,864,000 |
| Dec 2024 | 199,614,000 | 9,075,000 | -17,481,000 | 388,971,000 | 319,674,000 | 69,652,000 | -22,202,000 |
| Dec 2023 | 130,193,000 | 811,000 | -24,411,000 | 312,164,000 | 241,753,000 | 70,766,000 | 3,840,000 |
| Dec 2022 | 88,595,000 | 1,919,000 | -14,086,000 | 157,378,000 | 130,138,000 | 27,595,000 | 1,705,000 |
TTM Snapshot
Revenues TTM
$275,594,000
NetIncome TTM
$-37,226,000
OpCashFlow TTM
—
Assets (Latest)
$416,816,000
Forward EPS
$2.09
Max Pain — expiry 2027-04-16 (volume-derived — Yahoo OI feed degraded)
max pain strike: $39.00 · spot: $32.16 · call volume: 1,897 · put volume: 94
Expected Move to 2027-04-16:
±$9.40
(29.23%) —
implied range
$22.76 –
$41.56
· ATM straddle on $32.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MRVI | MARAVAI LIFESCIENCES HOLDINGS, INC. | $1.09B | $7.28 | — |
| CMPS | COMPASS Pathways plc | $1.13B | $7.98 | — |
| OPK | OPKO HEALTH, INC. | $1.20B | $1.62 | — |
| MTRI | InMed Pharmaceuticals Inc. | $1.02B | $17.50 | — |
| SLNCF | Silence Therapeutics plc | $1.22B | $6.53 | — |
News headlines (Yahoo Finance, 1h cache)
Harrow (HROW) Stock Still Looks Undervalued As Its 229% Three Year Run Continues
2026-11-13 13:10 · Yahoo
Harrow to Participate in Two Investor Conferences in November
2026-11-12 12:00 · Yahoo
Harrow Inc (HROW) Q3 2026 Earnings Call Highlights: Record Revenue of $99. ...
2026-11-11 07:04 · Yahoo
Harrow (HROW) Q3 2026 Earnings Call Transcript
2026-11-10 20:34 · Yahoo
Harrow Q3 Earnings Call Highlights
2026-11-10 15:15 · Yahoo
Harrow (HROW) Reports Q3 Earnings: What Key Metrics Have to Say
2026-11-09 23:00 · Yahoo
Harrow (HROW) Q3 Earnings Lag Estimates
2026-11-09 22:35 · Yahoo
Harrow: Q3 Earnings Snapshot
2026-11-09 21:33 · Yahoo
Harrow (HROW) Launches HarrowRx, Is The Stock Still Undervalued?
2026-11-07 14:12 · Yahoo
Learn Why The Bull Case For Harrow (HROW) Could Change Following Pharmacy Platform Launch
2026-11-05 02:10 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.